Keywords: generic, threats, sanofi-synthelabo, major, antithrombotic, plavix, france

Generic threats to Sanofi-Synthelabo's major antithrombotic Plavix?

Article | 18 February 2002

Print This

France's Sanofi-Synthelabo's share price took a tumble on the ParisBourse earlier this month on fears of generic competition for its ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in